Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Laser bioprinting device and in vivo applications

Ziel

PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics.

The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues. The bioprinter system is associated with protocols for cell isolation from autologous biopsies, cell expansion in-vitro, and cell printing in-vivo.

This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions. D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-EIC-2022-ACCELERATOR-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

PHOSPRINT ANONYMI ETAIREIA
Netto-EU-Beitrag
€ 2 000 560,00
Adresse
Patriarchou Grigoriou E’ & Neapoleos 27
153 41 AGIA PARASKEVI ATHINA
Griechenland
KMU
Ja
Region
Αττική Aττική Βόρειος Τομέας Αθηνών
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 2 857 943,38